Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-negative Breast Cancer|ER Positive Breast Cancer|PR-Positive Breast Cancer
Interventions: DRUG: Infigratinib|DRUG: Tamoxifen|DRUG: Omnipaque 350|DRUG: Iopamidol|DIAGNOSTIC_TEST: Computed tomography (CT)
Sponsor: Jennifer Lee Caswell-Jin
Collaborators: National Cancer Institute (NCI)|QED Therapeutics, Inc.